Tenaya Therapeutics, Inc. (TNYA) Reports Q4 EPS of (12c), In Line with Consensus

Group 1 - Tenaya Therapeutics, Inc. reported Q4 EPS of (12c), matching the consensus estimate, and expressed optimism for 2026 following clinical progress in 2025 [1] - The CEO highlighted upcoming updates in the first half of 2026, including long-term data from the MyPEAK-1 trial of TN-201 and new data from the RIDGE-1 trial of TN-401 [1] - Tenaya presented preclinical data for TN-301, a selective HDAC6 inhibitor, showing improvements in muscle performance and cardiac-related cellular function in models of Duchenne muscular dystrophy [2] Group 2 - Tenaya Therapeutics focuses on developing gene and small molecule therapies targeting heart disease, specifically cardiomyopathies and heart failure [3]